Innovation in Cervical Cancer Prevention and Control in Mexico

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 486-492

  Lazcano Ponce, Eduardo ^a   Allen Leigh, Betania ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Cervical cancer; Control; HPV; Prevention

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ACCREDITATION; CANCER CONTROL; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH DISPARITY; HEALTH PROGRAM; HUMAN; MEXICO; PAPANICOLAOU TEST; PERSISTENT VIRUS INFECTION; PREDICTION; PRIMARY PREVENTION; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MEXICO; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 70350051194     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.07.007     Document Type: Review

References (81)

1. Newmann S.J., and Garner E.O. Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control 16 (2005) 63-70
2. Chu K.C., Miller B.A., and Springfield S.A. Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc 99 (2007) 1092-1100 1102-1104
3. Yabroff K.R., Lawrence W.F., King J.C., et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment?. J Rural Health 21 (2005) 149-157
4. Ward E., Jemal A., Cokkinides V., et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54 (2004) 78-93
5. Dietsch E., Gibb H., and Francis K. Abnormal Pap test results and the rurality factor. Aust J Rural Health 11 (2003) 50-56
6. Friedell G.H., Tucker T.C., McManmon E., et al. Incidence of dysplasia and carcinoma of the uterine cervix in an Appalachian population. J Natl Cancer Inst 84 (1992) 1030-1032
7. Doescher M.P., and Jackson J.E. Trends in cervical and breast cancer screening practices among women in rural and urban areas of the United States. J Public Health Manag Pract 15 (2009) 200-209
8. Binns P.L., and Condon J.R. Participation in cervical screening by indigenous women in the Northern Territory: a longitudinal study. Med J Aust 185 (2006) 490-494
9. Wain G., Morrell S., Taylor R., et al. Variation in cervical cancer screening by region, socio-economic, migrant and indigenous status in women in New South Wales. Aust NZ J Obstet Gynaecol 41 (2001) 320-325
10. Coory M.D., Fagan P.S., Muller J.M., et al. Participation in cervical cancer screening by women in rural and remote Aboriginal and Torres Strait Islander communities in Queensland. Med J Aust 177 (2002) 544-547
11. Palacio-Mejía L.S., Rangel-Gómez G., Hernández-Avila M., et al. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex 45 suppl 3 (2003) S315-S325
12. Bray F., Loos A.H., McCarron P., et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14 (2005) 677-686
13. Hristova L., and Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 36 suppl 9 (1997) 1-60
14. Peto J., Gilham C., Fletcher O., et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (2004) 249-456
15. Sankaranarayanan R., Budukh A.M., and Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 79 (2001) 954-962
16. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 suppl 10 (2008) K29-K41
17. Gravitt P.E., Coutlée F., Iftner T., et al. New technologies in cervical cancer screening. Vaccine 26 suppl 10 (2008) K42-K52
18. Parkin D.M., Almonte M., Bruni L., et al. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin American and Caribbean region. Vaccine 26 suppl 11 (2008) L1-L15
19. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase 11 efficacy trial. Lancet Oncol 6 (2005) 271-278
20. Harper D., Franco E., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
21. Palacio-Mejía L.S., Lazcano-Ponce E., Allen-Leigh B., et al. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Publica Mex 51 suppl 2 (2009) S208-S219
22. Lazcano-Ponce E., Palacio-Mejia L.S., Allen-Leigh B., et al. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev 17 (2008) 2808-2817
23. Salmerón J., Lazcano-Ponce E., Lorincz A., et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14 (2003) 505-512
24. Eltoum I.A., and Roberson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer 111 (2007) 34-40
25. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10 year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
26. Moriarty A.T., Schwartz M.R., Eversole G., et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. Arch Pathol Lab Med 132 (2008) 1290-1244
27. Villa L.L., and Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gyn Obstet 94 suppl 1 (2006) S71-S80
28. Adams M., Jasani B., and Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 25 (2007) 3007-3013
29. Herrero R., Ferreccio C., Salmerón J., et al. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine 26 suppl 11 (2008) L49-L58
30. Ogilvie G.S., Patrick D.M., Schulzer M., et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 81 (2005) 207-212
31. Anhang R., Nelson J.A., Telerant R., et al. Acceptability of self-collection of specimens for HPV DNA testing in an urban population. J Womens Health (Larchmt) 14 (2005) 721-728
32. Dzuba I.G., Díaz E.Y., Allen B., et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 11 (2002) 265-275
33. Waller J., McCaffery K., Forrest S., et al. Acceptability of unsupervised HPV self-sampling using written instructions. J Med Screen 13 (2006) 208-213
34. Barata P.C., Mai V., Howlett R., et al. Discussions about self-obtained samples for HPV testing as an alternative for cervical cancer prevention. J Psychosom Obstet Gynaecol 29 (2008) 251-257
35. Wikström I., Stenvall H., and Wilander E. Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening. Acta Obstet Gynecol Scand 86 (2007) 720-725
36. Lazcano-Ponce E.C., Moss S., Alonso de Ruíz P., et al. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res 30 (1999) 240-250
37. Lazcano-Ponce E.C., Alonso de Ruíz P., López-Carrillo L., et al. Validity and reproducibility of cytologic diagnosis in a sample of cervical cancer screening centers in Mexico. Acta Cytol 41 (1997) 277-284
38. Lazcano-Ponce E.C., de Ruiz P.A., Lopez-Carrillo L., et al. Quality control study on negative gynecological cytology in Mexico. Diagn Cytopathol 10 (1994) 10-14
39. Krieger P., and Naryshkin S. Random rescreening of cytologic smears: a practical and effective component of quality assurance programs in both large and small cytology laboratories. Acta Cytol 38 (1994) 291-298
40. Lazcano-Ponce E.C., Buiatti E., Nájera-Aguilar P., Alonso-de-Ruiz P., et al. Evaluation model of the Mexican national program for early cervical cancer detection and proposals for a new approach. Cancer Causes Control 9 (1998) 241-251
41. Madrigal de la Campa Mde L., Lazcano Ponce E.C., and Infante Castañeda C. Overuse of colposcopy service in Mexico. Ginecol Obstet Mex 73 (2005) 637-647
42. Deizell Jr. J.E., Pereira S.L., and Ruplinger J. Colposcopy 101: a didactic curriculum to complement the clinical experience. Fam Med 33 (2001) 658-660
43. Caruthers B.S., and Sheets K.J. Development of a curriculum in colposcopy. J Fam Pract 32 (1991) 590-597
44. Spitzer M., Apgar B.S., Brotzman G.L., et al. Residency training in colposcopy: a survey of program directors in obstetrics and gynecology and family practice. Am J Obstet Gynecol 185 (2001) 507-513
45. Brotzman G.L., and Apgar B.S. Assessing colposcopic skills: the instructor's handbook. Fam Med 30 (1998) 350-355
46. Pagliusi S.R., Dillner J., Pawlita M., et al. Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 suppl 3 (2006) 193-200
47. Lowy D.R., Solomon D., Hildesheim A., et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113 7 suppl (2008) 1980-1993
48. Kotaniemi-Talonen L., Malila N., Nieminen P., et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 123 (2008) 2902-2906
49. Jhala D., and Eltoum I. Barriers to adoption of recent technology in cervical screening. Cytojournal 4 (2007) 16
50. Zapka J.G., Puleo E., Taplin S., et al. Breast and cervical cancer screening: clinicians' views on health plan guidelines and implementation efforts. J Natl Cancer Inst Monogr 35 (2005) 46-54
51. Goins K.V., Zapka J.G., Geiger A.M., et al. Implementation of systems strategies for breast and cervical cancer screening services in health maintenance organizations. Am J Manag Care 9 (2003) 745-755
52. Dabash R., Vajpayee J., Jacob M., et al. A strategic assessment of cervical cancer prevention and treatment services in 3 districts of Uttar Pradesh. India. Reprod Health 2 (2005) 11
53. Arillo-Santillan E., Nigenda G., Sanchez-Prado V.M., et al. Mexico City physicians' awareness about cervical cancer prevention: implications for cancer screening. J Cancer Educ 16 (2001) 75-79
54. Gany F., Trinh-Shevrin C., and Aragones A. Cancer screening and Haitian immigrants: the primary care provider factor. J Immigr Minor Health 10 (2008) 255-261
55. Shell R., and Tudiver F. Barriers to cancer screening by rural Appalachian primary care providers. J Rural Health 20 (2004) 368-373
56. Ka'ano'i M.E., Braun K.L., and Gotay C.C. Primary care physicians' knowledge, attitudes and practices related to cancer screening and cancer prevention clinical trials. Pac Health Dialog 11 (2004) 160-165
57. Holland-Barkis P., Forjuoh S.N., Couchman G.R., et al. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med 42 (2006) 140-145
58. Goldzweig C.L., Parkerton P.H., Washington D.L., et al. Primary care practice and facility quality orientation: influence on breast and cervical cancer screening rates. Am J Manag Care 10 (2004) 265-272
59. Ahmad F., Stewart D.E., Cameron J.I., et al. Rural physicians' perspectives on cervical and breast cancer screening: a gender-based analysis. J Womens Health Gend Based Med 10 (2001) 201-208
60. Cochran C.R., and Gorospe E.C. Physician satisfaction in a cancer prevention program for low-income women in Nevada. Sci World J 7 (2007) 177-186
61. Gorospe E.C., Cochran C.R., and Cabb E.E. Factors for satisfaction among providers of ancillary health services in a community-based cancer prevention program: a pilot study in Nevada. Sci World J 6 (2006) 727-733
62. Laurant M., Reeves D., Hermens R., et al. Substitution of doctors by nurses in primary care. Cochrane Database Syst Rev (2005) CD001271
63. Dierick-van Daele A.T., Metsemakers J.F., Derckx E.W., et al. Nurse practitioners substituting for general practitioners: randomized controlled trial. J Adv Nurs 65 (2009) 391-401
64. Horrocks S., Anderson E., and Salisbury C. Systematic review of whether nurse practitioners working in primary care can provide equivalent care to doctors. BMJ 324 (2002) 819-823
65. Tsu V.D., and Levin C.E. Making the case for cervical cancer prevention: what about equity?. Reprod Health Matters 16 (2008) 104-112
66. Goldie S.J., O'Shea M., Diaz M., et al. Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 16 (2008) 86-96
67. Perez G., Lazcano-Ponce E., Hernandez-Avila M., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 122 (2008) 1311-1318
68. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
69. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
70. Hildesheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
71. Giuliano A.R., Lazcano-Ponce E., Villa L., et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196 (2007) 1153-1162
72. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
73. Schiller J.T., Castellsagué X., Villa L.L., et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 suppl 10 (2008) K53-K61
74. Kovács K., Varnai A.D., Bollmann M., et al. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5 year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol 80 (2008) 1814-1823
75. Sigurdsson K., Sigvaldason H., Gudmundsdottir T., et al. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. Acta Obstet Gynecol Scand 88 (2008) 27-35
76. Rambout L., Hopkins L., Hutton B., et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177 (2007) 469-479
77. Dessy F.J., Giannini S.L., Bougelet C.A., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 4 (2008) 425-434
78. Chesson H.W., Forhan S.E., Gottlieb S.L., et al. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26 (2008) 4513-4518
79. Andrews E., Seaman W.T., and Webster-Cyriaque J. Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. Oral Oncol 45 (2009) 486-491
80. Feltkamp M.C., de Koning M.N., Bavinck J.N., et al. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 43 (2008) 353-360
81. Paavonen J. Future II Study Group. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin 24 (2008) 1623-1634